Interactive Investor
>>

Editas Medicine Inc (NASDAQ:EDIT) Share Price

EDIT

Editas Medicine Inc

North American company

Right Arrow 1

Healthcare

Right Arrow 2

Biotechnology

Bid

-

Ask

-

Last Traded

-

Chg

-

-

XNAS

-

Updated: -

Research

News & analysis

Loading...

Times are shown in GMT-4, values are delayed by at least 15 minutes. Past performance is not a reliable indicator of future results.

Company Profile

Editas Medicine Inc is a gene-editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company's only operating segment being developing and commercializing genome editing technology.Editas Medicine Inc is a genome editing company which is engaged in treating patients with genetically defined diseases by correcting disease-causing genes.

NASDAQ:EDIT

US28106W1036

USD

Loading...

Loading Comparison

Latest EDIT News